FILTER
FILTERED INTERVIEW RESULTS
Dean McPherson
HEAD, BUSINESS DEVELOPMENT, GLOBAL MINING, TMX GROUP
TMX Group speaks to GBR about the mining sector’s upswing and the capital raising models that junior companies are presently using.
Pat Dubreuil &Richard Murphy
PRESIDENT & CEO, MANITOU GOLD
Manitou Gold is exploring the Goudreau-Lochalsh Deformation Zone and discusses its plans with GBR.
Michael Gribbons & David Ballantyne
VP & CO-FOUNDERs, MAESTRO DIGITAL MINE
Maestro Digital Mine explains to GBR how a wide range of digital solutions can benefit mining.
Craig Parry
PRESIDENT AND CEO, ISO ENERGY
Uranium miner ISO Energy explain its plans for exploring and developing its properties in the eastern Athabasca basin.
Patrick Soares
FORAN MINING
Foran mining continue to expand the resource bace at its McIlvenna Bay property in preparation for an upturn.
Gorden Glenn
CHAIRMAN, PRESIDENT AND CEO, MINNOVA CORP.
Minnova explains to GBR how it is planning to speedily bring to production its PL gold mine in Manitoba.
Hon. Blaine Pedersen
MINISTER OF GROWTH, ENTERPRISE AND TRADE, MANITOBA GOVERNMENT
The new Government of Manitoba is determined to bring business to the province and is focusing on mining potential.
Andre Lauzon
VP MANITOBA BUSINESS UNIT, HUDBAY MINERALS
Hudbay Minerals has been mining in Manitoba for more than 90 years and continues exploring the province.
John Mannarino & Jim Palmer
MANNARINO SYSTEMS & SOFTWARE INC.
Mannarino develops flight-critical level-A software.
Serge Beaudoin and Richard Arès
UNIVERSITY OF SHERBROOKE
University of Sherbrooke places particular emphasis on ensuring practical experience for its students.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
